Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the Fre...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F ») Daix (France), New York City (New York, Etats-Unis), le 8 avril 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui avoir déposé son Document d’Enregistrement Universel 2025 pour l’exercice clos le 31 décembre 2025, incluant le rapport de gestion et le rapp...
We view Ontex as "Medium Risk" on the LARA scale. The group benefits from its leading position in the hygiene disposables market in Europe and growing presence in North America. Ontex has decent geographical and product diversification. Customer concentration is low, and supplier concentration is modest. The company has greater exposure to developed markets, which have slower growth rates, and remains vulnerable to raw-material price volatility and high fixed costs. Ontex's credit profile has re...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 7, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cov...
Ontex convenes its annual general shareholders’ meeting Regulated information Aalst, Belgium, April 3, 2026 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, convenes its annual general shareholders’ meeting on Tuesday, May 5, 2026, at 14:00 CEST. The meeting will take place at the company’s headquarters, located at Korte Keppestraat 21, 9320 Aalst in Belgium. The agenda, proposed resolutions and other documents relating to the annual general shareholders’ meeting are available on Enquiries InvestorsGeoffroy Raskin Media...
Ontex roept haar gewone algemene aandeelhoudersvergadering bijeen Gereglementeerde informatie Aalst, België, 3 april 2026 – Ontex Group NV [EURONEXT: ONTEX], een toonaangevende ontwikkelaar en producent van persoonlijke verzorgingsproducten roept haar gewone algemene aandeelhoudersvergadering bijeen op dinsdag 5 mei 2026 om 14.00 uur (CEST). Deze vergadering vindt plaats op haar hoofdzetel in de Korte Keppestraat 21, 9320 Aalst. De agenda, voorgestelde resoluties en andere documenten met betrekking tot de gewone algemene aandeelhoudersvergadering zijn beschikbaar op . Contact Investee...
Inventiva's FY25 results come with narrowed timeline guidance for the topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which is expected in 4Q26 (previously 2H26). We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the MASH commercial opportunity. Inventiva confirmed its cash runway guidance to middle of 1Q27, beyond the key milestone...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 31, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Barco continues to face weak demand in Healthcare and Enterprise, while we believe that Entertainment momentum is likely to fade as tariffs, a weak USD and fallout from the Iran conflict soften performance. The sizeable VerVent Audio acquisition, prioritised over buybacks, limits capital allocation flexibility. Although we believe the valuation at 11x PER 2027F is undemanding, the lack of a sustainable return to growth caps near-term upside. We reduce our target price to €10 per share (from €16)...
Inventiva reports 2025 full year results and provides a business update Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical tr...
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme1 au 31 décembre 2025Réalisation d'une offre au public aux États-Unis pour un produit brut d'environ 172,5 millions de dollars (149 millions d'euros2)Horizon de trésorerie prévu jusqu’au milieu du premier trimestre 20273Finalisation de la cession d'odiparcil avec des paiements d’étapes potentiels pouvant atteindre 90 millions de dol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.